METiS Therapeutics in-licensed global rights to a pan-RAF inhibitor program from Korea’s Voronoi in a deal worth up to $482 million. METiS will pay only $1.7 million upfront, with provision for $480.5 million in milestone payments, plus royalties.

In SPAC news this week, AgiiPlus and Goldenbridge Acquisition announced a merger agreement, while Billy Beane's RedBall confirmed it is in talks to potentially bring SeatGeek public.